stockrowIovance Biotherapeutics, Inc.
IOVA Healthcare Biotechnology
Iovance Biotherapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $263.5 million, up 60.6% from fiscal 2024.
- Revenue
- +80.1%
- EPS
- +80.0%
- Free cash flow
- +89.7%
Quarter to September 2026, against a year earlier
Follow IOVA
Alert me
Iovance Biotherapeutics, Inc. (IOVA) Return on equity
Iovance Biotherapeutics, Inc.'s return on equity over the twelve months to 30 September 2026 was −29.1%, up 26.4 percentage points from fiscal 2025 (−55.5%). Over the past ten years it has ranged from −81.9% (fiscal 2023) to −37.2% (fiscal 2015); the current reading is higher than 55% of that period. That is above the Biotechnology industry median of −50.1% and below the Healthcare sector median of −26.3%.
Return on equity, annual
Embed this chart
Annual newest first
| Period | Return on equity | Change (points) |
|---|---|---|
| FY2025 | −55.5% | 1.98 |
| FY2024 | −57.5% | 24.43 |
| FY2023 | −81.9% | (11.30) |
| FY2022 | −70.6% | (17.06) |
| FY2021 | −53.6% | 0.79 |
| FY2020 | −54.3% | (2.70) |
| FY2019 | −51.6% | (11.23) |
| FY2018 | −40.4% | 18.53 |
| FY2017 | −58.9% | 16.61 |
| FY2016 | −75.6% | (38.39) |
Against its own ten years
Return on equity against peers
| Company | Return on equity |
|---|---|
| ACAD ACADIA Pharmaceuticals Inc. compare | 31.4% |
| PBLS Parabilis Medicines, Inc. compare | 0.00% |
| ABCL AbCellera Biologics Inc. compare | −17.3% |
| TNGX Tango Therapeutics, Inc. compare | −21.3% |
| IOVA Iovance Biotherapeutics, Inc. | −29.1% |
| RLAY Relay Therapeutics, Inc. compare | −36.8% |
| EWTX Edgewise Therapeutics, Inc. compare | −38.0% |
| IRON Disc Medicine, Inc. compare | −39.1% |
| XENE Xenon Pharmaceuticals Inc. compare | −43.6% |
| Biotechnology industry median | −50.1% |
| Healthcare sector median | −26.3% |
| Market median | 0.51% |
What Return on equity is
ROE shows how much profit a company earns for its shareholders on the equity they have in the business.
Annual: Net Income Allotted to Shareholders ÷ Average Common Equity; TTM: Net Income Allotted to Shareholders ÷ Average Common Equity (latest quarter)
More on IOVA
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Altman Z-score
- The full statement